Vibegron was first discovered by scientists at Merck & Co. Inc.[7] and was later developed in Japan by Kyorin Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, and Urovant Sciences.[8] It was approved for medical use in Japan in September 2018,[8] in the United States in December 2020,[1][5][6] and in the European Union in June 2024.[2]
Efficacy
Vibegron, once daily 75 mg provided significant reduction in micturition, urgency episodes and urge incontinence, and increased the volume per micturition.[9]
Medical uses
Vibegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.[1][5][6]
Safety
Generally, the introduction of β3 adrenergic receptors agonists such as vibegron has improved overactive bladder (OAB) management by minimizing anticholinergic-related adverse effects.[10] Monotherapy with a β3 adrenergic agonist may be preferred in older patients, those with high anticholinergic burden, and older adults with multiple comorbidities.[11] An ambulatory blood pressure monitoring study showed that treatment with vibegron was not associated with clinically meaningful effects on blood pressure or heart rate. Treatment with vibegron was also associated with improvements in patient-reported measures of quality of life. Vibegron was generally effective, safe and well tolerated, thus represents a valuable treatment option for patients with OAB.[12]
Vibegron is, in contrast to other OAB drugs, very selective and leads to a lesser degree of unwanted side effects. Vibegron is found to be a substrate for CYP3A4 in vivo, but does not actually induce or inhibit any of the cytochrome P450 enzymes and is thus less likely to take part in drug–drug interactions (DDI). Here vibegron differs from the previous overactive bladder drug mirabegron, which was known to be associated in various drug–drug interactions by inhibiting CYP2D6 or inducing CYP3A4, CYP2D6 and CYP2C9 in the liver.[13][4][14][15][16][17]
Using vibegron only (monotherapy) has positive effects on OAB and UUI, but a combination with other drugs can have additional effects. In a study with antimuscarinic drugs, more DDIs were investigated using a model of rhesus monkeys. Dose combinations of vibegron and tolterodine showed increased bladder capacity, the effects of both drugs at low doses strengthened each other, known as synergism. The addition of darifenacin to vibegron created greater bladder relaxation only when used at high doses.[18] Additionally, co-administration with imidafenacin shows an increase in bladder capacity and voided volume in comparison to monotherapy.[18] Possibly, a widely adapted treatment will be the combination of beta-3-adrenergic agonist with a nonselective M2/M3 antagonist as the most prevalent option.[4]
Clinical studies show no significant drug–drug interaction, aside from a serum concentration increase of digoxin when taken with vibegron. Maximal concentrations and systemic exposure (Cmax and area under the curve (AUC)) of digoxin are both increased as a result of DDI.[19][1] Apart from the no to little DDIs, vibegron has an additional safety quality in that it does not cross the blood-brain barrier and therefore does not induce cognitive impairment.[4] Furthermore, vibegron can be taken with or without food, this does not have an effect on vibegron plasma concentrations.[1][19]
Pharmacology
Mechanism of action
Vibegron is a selective agonist for the beta-3 adrenergic receptor. The receptors are located in the kidneys, urinary tract and bladder tissue.[20] Upon binding, the β3 receptor undergoes a conformational change. This induces the activation of adenylate cyclases via G proteins and thereby promotes the formation of cyclic adenosine monophosphate (cAMP). The consequence of this cascade is an increased intracellular cAMP concentration, which triggers activation of cAMP-dependent protein kinase A and causes a reduction of Ca2+ concentration in the cytoplasm. The kinase then phosphorylatesmyosin chains and thereby inhibits muscle contraction.[4]
The final effect of vibegron is muscle relaxation in the bladder. Due to this muscle relaxation, bladder capacity increases and symptoms of overactive bladder are relieved.[17]
Pharmacokinetics
The two main metabolic pathways are the oxidation and glucuronidation of vibegron. Two oxidative metabolites and three glucuronide metabolites can be formed. The exact structure of these metabolites have not been studied yet.[4] In vitro, CYP3A4 is the enzyme responsible for the metabolism of vibegron, facilitating oxidative metabolism. Eventually, still a large part of the unmodified drug is excreted through feces and urine.[1]
History
The beta-3 adrenergic receptor (beta3AR) was discovered in the late 1980s[20] and initially, beta3AR agonists were investigated as treatment for obesity and diabetes.[21] A number of compounds were tested in clinical trials but didn't show sufficient benefits in these areas.[21]
A phase IIb global trial completed in 2013 of 1395 patients, of which 89.7% were women and 63.3% had not been treated previously, demonstrated a significant decrease in daily micturitions and urgent urinary incontinence episodes upon administration of vibegron.[22][13]
An international phase III trial of 506 participants completed in 2019 found statistically significant efficacy of vibegron after two weeks of daily administration. The adverse effect rates in participants treated with vibegron were comparable to those in participants who received a placebo.[23]
Vibegron was evaluated in patients with OAB in several clinical studies. A large active-controlled study, called Empower, showed the beneficial effects of the drug to treat the condition and UUI.[1][4] Primary outcomes of different clinical trials showed there was an overall increase in efficacy. These outcomes concluded that there was a reduction in urgency to urinate, a decrease in micturitions and a decrease in average volume voided per micturition.[1] There is also an improvement observed of the symptoms when vibegron is administered over a longer period (52 weeks) concluding that it is effective and safe for longer use.[17] In severe patients, increasing the dose was accompanied by similar beneficial effects when there was first a lack of these.[24]Quality of life of the patients is improved, including a reduction of nocturia.[17]
Society and culture
Legal status
Vibegron was developed in Japan by Kyorin Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, and Urovant Sciences.[8] It was approved for medical use in Japan in September 2018,[8] and in the United States in December 2020.[1][5][6]
In April 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Obgemsa, intended for the symptomatic treatment of adults with overactive bladder (OAB) syndrome.[2][25] The applicant for this medicinal product is Pierre Fabre Medicament.[2] Vibegron was approved for medical use in the European Union in June 2024.[2]
Pregnant rats were given very high daily oral doses of vibegron during the period of organogenesis and showed no embryo-fetal developmental toxicity up to 300 mg/kg/day. Similar data was found in rabbits. Maternal toxicity was observed when doses exceeded 100 mg/kg/day in lactating rats. Clinical studies show that vibegron is not toxic, safe and well-tolerated in patients.[1]
^ abcde"Obgemsa EPAR". European Medicines Agency. 25 April 2024. Archived from the original on 5 July 2024. Retrieved 27 April 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Obgemsa PI". Union Register of medicinal products. 28 June 2024. Retrieved 5 July 2024.
^Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN (August 2020). "International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR". The Journal of Urology. 204 (2): 316–324. doi:10.1097/ju.0000000000000807. PMID32068484. S2CID211161769.
^ abMitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S, et al. (February 2019). "Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial". European Urology. 75 (2): 274–282. doi:10.1016/j.eururo.2018.10.006. PMID30661513. S2CID58547754.{{cite journal}}: CS1 maint: overridden setting (link)
^ abEdmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, et al. (January 2016). "Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder". Journal of Medicinal Chemistry. 59 (2): 609–23. doi:10.1021/acs.jmedchem.5b01372. PMID26709102.{{cite journal}}: CS1 maint: overridden setting (link)
^Clinical trial number NCT01314872 for "A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)" at ClinicalTrials.gov
^Clinical trial number NCT03583372 for "An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (Empowur) " at ClinicalTrials.gov
^Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T (May 2018). "Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study". European Urology. 73 (5): 783–790. doi:10.1016/j.eururo.2017.12.022. PMID29366513.
^World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3): 318. hdl:10665/331167.
External links
Clinical trial number NCT03492281 for "A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)" at ClinicalTrials.gov
Giuseppe PellaGiuseppe Pella nel 1963 Presidente del Consiglio dei ministri della Repubblica ItalianaDurata mandato17 agosto 1953 –19 gennaio 1954 Capo di StatoLuigi Einaudi PredecessoreAlcide De Gasperi SuccessoreAmintore Fanfani Vicepresidente del Consiglio dei ministri della Repubblica ItalianaDurata mandato19 maggio 1957 –1º luglio 1958 Capo del governoAdone Zoli PredecessoreGiuseppe Saragat SuccessoreAntonio Segni Ministro delle finanzeDurata mandato6 g…
Kementerian Buruh, Urusan Sosial dan Layanan Sosial Israelמשרד העבודה, הרווחה והשירותים החברתייםInformasi lembagaDibentuk1948Wilayah hukumPemerintahan IsraelMenteriTBDSitus webwww.molsa.gov.il Kementerian Buruh, Urusan Sosial dan Layanan Sosial (Ibrani: משרד העבודה, הרווחה והשירותים החברתייםcode: he is deprecated , Misrad HaAvoda, HaRevaha VeHaSherutim HaHevrati'im) adalah cabang pemerintahan yang bertugas mengurusi pekerjaan dan …
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Oktober 2022. Dramyin Dramyin atau dramyen (Tibet: སྒྲ་སྙན་; Wylie: sgra-snyan; Dzongkha: dramnyen; Hanzi: 扎木聂; Pinyin: zhamunie)[1] adalah sebuah alat musik rakyat Himalaya tradisional dengan enam senar, digunakan ter…
Merpati Nusantara Airlines Flight 5601PK-MND, kapal lain yang mirip dengan yang mengalami kecelakaanRingkasan accidentTanggal18 Oktober 1992 (1992-10-18)RingkasanPenerbangan dikendalikan ke daratanLokasiGunung Papandayan, 30 km di barat Garut Jawa Barat, IndonesiaPenumpang27Awak4Tewas31Selamat0Jenis pesawatCASA/IPTN CN-235-100OperatorMerpati Nusantara AirlinesRegistrasiPK-MNNAsalBandar Udara Internasional Achmad Yani, Semarang, IndonesiaTujuanBandar Udara Internasional Husein Sastraneg…
Parc éolien de l'EscrebieuxLes quatre éoliennes du parc mi-juillet 2021.AdministrationLocalisation Esquerchin, Nord FranceCoordonnées 50° 23′ 58″ N, 2° 59′ 39″ ECaractéristiquesType d'installation Parc éolien terrestre (d)modifier - modifier le code - modifier Wikidata Le parc éolien de l'Escrebieux est un parc éolien terrestre construit de 2020 à 2021 et sis sur les finages des communes d'Esquerchin, Flers-en-Escrebieux et Courcelles-lès-Len…
I WishPoster filmSutradaraHirokazu Kore-edaProduserKentarō KoikeHijiri TaguchiDitulis olehHirokazu Kore-edaPenata musikKishida ShigeruSinematograferYutaka YamasakiPenyuntingHirokazu Kore-edaPerusahaanproduksiShirogumi Inc.BIGXDistributorGagaTanggal rilis 11 Juni 2011 (2011-06-11) (Jepang) Durasi127 menitNegaraJepangBahasaJepangPendapatankotor$1,543,385[1] I Wish (奇跡code: ja is deprecated , Kiseki, terj. har.Miracle) adalah film Jepang tahun 2011 yang disunting, dituli…
Branch of differential geometry and differential topology Phase portrait of the Van der Pol oscillator, a one-dimensional system. Phase space was the original object of study in symplectic geometry. Symplectic geometry is a branch of differential geometry and differential topology that studies symplectic manifolds; that is, differentiable manifolds equipped with a closed, nondegenerate 2-form. Symplectic geometry has its origins in the Hamiltonian formulation of classical mechanics where the pha…
Questa voce o sezione sull'argomento edizioni di competizioni calcistiche non cita le fonti necessarie o quelle presenti sono insufficienti. Puoi migliorare questa voce aggiungendo citazioni da fonti attendibili secondo le linee guida sull'uso delle fonti. Segui i suggerimenti del progetto di riferimento. Scottish Challenge Cup 2014-2015Petrofac Training Cup 2014-2015 Competizione Scottish Challenge Cup Sport Calcio Edizione 24ª Organizzatore Scottish Professional Football League Date dal&…
Christian Ziege Informasi pribadiTanggal lahir 1 Februari 1972 (umur 52)Tempat lahir Berlin, JermanTinggi 1,86 m (6 ft 1 in)Posisi bermain GelandangInformasi klubKlub saat ini Borussia Mönchengladbach(Direktur Sepak bola)Karier junior1978–19811981–19851985–1990 FC Südstern 08 BerlinTSV Rudow BerlinFC Hertha 03 ZehlendorfKarier senior*Tahun Tim Tampil (Gol) 1990–19971997–19991999–20002000–20012001–20042004–2005 Bayern MunichA.C. MilanMiddlesbroughLiverpool …
Глиссирующая моторная лодка Катер Antares-8.80 с двумя подвесными моторами общей мощностью до 300 л. с. Мото́рная ло́дка — маломерное судно, оборудованное подвесным мотором. Наличие именно легкосъёмного подвесного мотора является единственным квалифицирующим признаком в…
Christianity's relationship with other world religions, and the differences and similarities. This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article or section possibly contains synthesis of material which does not verifiably mention or relate to the main topic. Relevant discussion may be found on the talk page. (March 2009) (Learn how and when to remove this template message) This art…
1976 duet by Elton John and Kiki Dee For other songs of this name and all other uses, see Don't Go Breaking My Heart (disambiguation). Don't Go Breaking My HeartSingle by Elton John and Kiki DeeB-sideSnow QueenReleased21 June 1976Recorded27 March 1976[1]Genre Disco[2] pop[2] Length4:31LabelRocket (UK)MCA (US)Songwriter(s) Elton John Bernie Taupin[a] Producer(s)Gus DudgeonElton John singles chronology Pinball Wizard (1976) Don't Go Breaking My Heart (1976) Sorr…
Lough GurLoch Goir (Irish)Location in IrelandLocationCounty LimerickCoordinates52°30′58.97″N 8°31′59.80″W / 52.5163806°N 8.5332778°W / 52.5163806; -8.5332778Basin countriesIrelandSurface area0.78 km2 (0.30 sq mi)Average depth1.5 m (4 ft 11 in)Max. depth3.8 m (12 ft)Water volume1.2 hm3 (970 acre⋅ft)Residence time0.21 years[1] Lough Gur (Irish: Loch Goir)[2] is a lake in County Li…
Questa voce o sezione sull'argomento centri abitati delle Marche non cita le fonti necessarie o quelle presenti sono insufficienti. Puoi migliorare questa voce aggiungendo citazioni da fonti attendibili secondo le linee guida sull'uso delle fonti. Sant'Angelo in Vadocomune Sant'Angelo in Vado – VedutaPanorama LocalizzazioneStato Italia Regione Marche Provincia Pesaro e Urbino AmministrazioneSindacoStefano Parri (lista civica) dal 22-9-2020 TerritorioCoordinate43°…
1883 territorial settlement between Chile and Peru Treaty of AncónTreaty of Friendship and Peace between the Republics of Chile and PeruTypePeace treatySigned20 October 1883 (1883-10-20)LocationAncón, PeruConditionRatification by Chile on 12–13 January and Peru on 8 March 1884Signatories José Antonio de Lavalle Mariano Castro Zaldívar [es] Jovino Novoa Vidal Parties Peru Chile DepositaryChilean and Peruvian GovernmentsLanguagesSpanish The Treaty of A…
National beauty contest in Ghana For the most recent edition, see Miss Grand Ghana 2022. Miss Grand GhanaFormationAugust 9, 2020; 3 years ago (2020-08-09)FounderSandy AmissahTypeBeauty pageantHeadquartersAccraLocationGhanaMembership Miss Grand InternationalOfficial language EnglishNational DirectorAbena AppiahParent organizationLegacy Pageants Limited (2020)Akuaba Entertainment (2022 – present) Abena Appiah, the national director of Miss Grand Ghana, since 2022 Miss…
Pour les articles homonymes, voir Bataille de Meaux. Charles IX attaqué par les protestants à Meaux. Enluminure du manuscrit Carmen de tristibus Galliae, 1577, Bibliothèque municipale de Lyon, ms. 0156, fo 13. La surprise de Meaux (aussi appelée la bataille de Meaux) est une conspiration organisée en 1567 par Louis Ier de Bourbon-Condé, un des principaux chefs protestants, pour enlever le roi de France, Charles IX, et la famille royale. Cet événement déclenche la deuxième guerre d…
Численность населения республики по данным Росстата составляет 4 003 016[1] чел. (2024). Татарстан занимает 8-е место по численности населения среди субъектов Российской Федерации[2]. Плотность населения — 59,00 чел./км² (2024). Городское население — 76,72[3] % (2022)…
